BioJENC innovates and develops new GP1-based cancer-related diagnostics and therapeutics.
GP1-based cancer diagnostics and therapeutics
New GP1-based immune biosensor is intended for multipurpose use; first use it to confirm the presence of granzyme B associated new biomarker in tumor cells, then use it to effect contactless NK/CTL anti-tumor immune response/immunity.
Publication online: WCJ Lo and DG Luther (2023) Detection of Granzyme B-associated Binding Targets in Peripheral Blood Samples of Hosts in Sickness and in Health Using a Granzyme B-like Peptide Fluorescent Conjugate (GPIR). Journal of Fluorescence https:doi.org/10.1007/s10895-023-03320-1
- The report shows that a proprietary immune biosensor has therapeutic potentials to specifically destroy tumor cells and it can also be used to facilitate immune cells in circulating blood giving out different signals in hosts in sickness and in health for use to correlate with their immune potentials to fight diseases including but not limited to cancer and infection. The ability to target tumor cells specifically for destruction is based on the binding affinity of this biosensor for a novel "epitope-like" of tumor antigens in tumor cells and its tumor cell specific cytotoxicity attribute. Unlike the targeted tumor cell specificity/cytotoxicity by design against a specific type of tumor cells used in the CAR T-cell technology and ADC technology, the tumor cell specificity/cytotoxicity of a GP1-based biosensor technology may have an inherent advantage to target different types of tumor cells.
For more information, please contact: JENNIFERLO.BIOJENC@GMAIL.COM
Copyright 2023 BioJENC All Rights Reserved